LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer

Endometrial cancer (EC) is the fourth most common cancer in women. Advanced-stage EC has limited treatment options with a poor prognosis. There is an unmet need for the identification of actionable drivers for the development of targeted therapies in EC. Leukemia inhibitory factor receptor (LIFR) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Weiwei, Ramasamy, Kumaraguruparan, Pillai, Sureshkumar M. A., Santhamma, Bindu, Konda, Swapna, Pitta Venkata, Prabhakar, Blankenship, Logan, Liu, Junhao, Liu, Zexuan, Altwegg, Kristin A., Ebrahimi, Behnam, Pratap, Uday P., Li, Xiaonan, Valente, Philip T., Kost, Edward, Sareddy, Gangadhara R., Vadlamudi, Ratna K., Nair, Hareesh B., Tekmal, Rajeshwar R., Viswanadhapalli, Suryavathi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367961/
https://www.ncbi.nlm.nih.gov/pubmed/34400617
http://dx.doi.org/10.1038/s41420-021-00603-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367961/
https://www.ncbi.nlm.nih.gov/pubmed/34400617
http://dx.doi.org/10.1038/s41420-021-00603-z

Ejemplares similares